PURPOSE: Fatigue is a common problem among multiple myeloma (MM) patients. Armodafinil is a drug known to promote wakefulness, which is related to modafinil, a compound that improves fatigue in some cancer patients treated with chemotherapeutic agents. We investigated whether armodafinil could reduce cancer-related fatigue in MM patients. METHODS: This double-blind, placebo-controlled phase 3 trial evaluated the efficacy of armodafinil in MM patients with evidence of moderate fatigue. Patients were randomized to one of two arms: treatment-only, with armodafinil given at 150 mg/daily for 56 days, or placebo-first, with placebo given on days 1-28, followed by armodafinil administered at 150 mg daily on days 29-56. Fatigue was measured on days 1 (pre-dose: baseline), 15, 28, 43, and 56 using seven separate assessments, including four patient-reported outcomes of fatigue and related quality of life measures, as well as three objective measures of cognitive function. RESULTS: Overall toxicities were similar between treatment groups. No significant differences were observed between the placebo-first and the treatment-only arms after 28 days. Treatment with armodafinil for 28 additional days did not produce responses. Both placebo-first and treatment-only patients showed similar significant improvements in three patient-reported measures and one objective task at day 28 compared to baseline. Placebo-first patients improved on eight additional measures (one patient-reported measure, six subscales, and one objective task), suggesting a strong placebo effect in this patient population. CONCLUSIONS: Evaluation and treatment of cancer-related fatigue continues to be challenging; a clear definition of this symptom and better assessment tools are needed.
PURPOSE: Fatigue is a common problem among multiple myeloma (MM) patients. Armodafinil is a drug known to promote wakefulness, which is related to modafinil, a compound that improves fatigue in some cancer patients treated with chemotherapeutic agents. We investigated whether armodafinil could reduce cancer-related fatigue in MM patients. METHODS: This double-blind, placebo-controlled phase 3 trial evaluated the efficacy of armodafinil in MM patients with evidence of moderate fatigue. Patients were randomized to one of two arms: treatment-only, with armodafinil given at 150 mg/daily for 56 days, or placebo-first, with placebo given on days 1-28, followed by armodafinil administered at 150 mg daily on days 29-56. Fatigue was measured on days 1 (pre-dose: baseline), 15, 28, 43, and 56 using seven separate assessments, including four patient-reported outcomes of fatigue and related quality of life measures, as well as three objective measures of cognitive function. RESULTS: Overall toxicities were similar between treatment groups. No significant differences were observed between the placebo-first and the treatment-only arms after 28 days. Treatment with armodafinil for 28 additional days did not produce responses. Both placebo-first and treatment-only patients showed similar significant improvements in three patient-reported measures and one objective task at day 28 compared to baseline. Placebo-first patients improved on eight additional measures (one patient-reported measure, six subscales, and one objective task), suggesting a strong placebo effect in this patient population. CONCLUSIONS: Evaluation and treatment of cancer-related fatigue continues to be challenging; a clear definition of this symptom and better assessment tools are needed.
Authors: O Paltiel; A Marzec-Boguslawska; V Soskolne; S Massalha; M Avitzour; R Pfeffer; N Cherny; T Peretz Journal: Qual Life Res Date: 2004-12 Impact factor: 4.147
Authors: Allen C Sherman; Stephanie Simonton; Umaira Latif; Thomas G Plante; Elias J Anaissie Journal: Biol Blood Marrow Transplant Date: 2009-01 Impact factor: 5.742
Authors: Yoon Jung Chang; Jung Suk Lee; Chang Geol Lee; Won Sup Lee; Keun Seok Lee; Soo-Mee Bang; Xin Shelley Wang; Tito R Mendoza; Charles S Cleeland; Young Ho Yun Journal: Support Care Cancer Date: 2007-07 Impact factor: 3.359
Authors: Anna Spathis; Kate Fife; Fiona Blackhall; Susan Dutton; Ronja Bahadori; Rose Wharton; Mary O'Brien; Patrick Stone; Tim Benepal; Nick Bates; Bee Wee Journal: J Clin Oncol Date: 2014-04-28 Impact factor: 44.544
Authors: Anita R Peoples; Sheila N Garland; Michael L Perlis; Josée Savard; Charles E Heckler; Charles S Kamen; Julie L Ryan; Karen M Mustian; Michelle C Janelsins; Luke J Peppone; Gary R Morrow; Joseph A Roscoe Journal: J Cancer Surviv Date: 2017-01-19 Impact factor: 4.442
Authors: Pedro Nazareth Aguiar Junior; Carmelia Maria Noia Barreto; Daniel de Iracema Gomes Cubero; Auro Del Giglio Journal: Support Care Cancer Date: 2019-07-13 Impact factor: 3.603
Authors: Nadia Miladi; Richi Dossa; Maman Joyce Dogba; Marie Immacula Fabienne Cléophat-Jolicoeur; Bruno Gagnon Journal: Support Care Cancer Date: 2019-06-28 Impact factor: 3.603
Authors: Heather S L Jim; Aasha I Hoogland; Hyo Sook Han; Eva Culakova; Charles Heckler; Michelle Janelsins; Geoffrey C Williams; Julienne Bower; Stephen Cole; Zeruesenay Desta; Margarita Bobonis Babilonia; Gary Morrow; Luke Peppone Journal: Contemp Clin Trials Date: 2020-03-05 Impact factor: 2.226
Authors: Sheila N Garland; Joseph A Roscoe; Charles E Heckler; Holly Barilla; Philip Gehrman; James C Findley; Anita R Peoples; Gary R Morrow; Charles Kamen; Michael L Perlis Journal: Sleep Med Date: 2015-12-31 Impact factor: 3.492
Authors: D Tomlinson; P D Robinson; S Oberoi; D Cataudella; N Culos-Reed; H Davis; N Duong; F Gibson; M Götte; P Hinds; S L Nijhof; P van der Torre; S Cabral; L L Dupuis; L Sung Journal: Curr Oncol Date: 2018-04-30 Impact factor: 3.677
Authors: Charles E Heckler; Sheila N Garland; Anita R Peoples; Michael L Perlis; Michelle Shayne; Gary R Morrow; Charles Kamen; Jenine Hoefler; Joseph A Roscoe Journal: Support Care Cancer Date: 2015-11-05 Impact factor: 3.359